2023-10-23 15:35:21 ET
More on Cel-Sci
- Seeking Alpha’s Quant Rating on Cel-Sci
- Historical earnings data for Cel-Sci
- Financial information for Cel-Sci
For further details see:
CEL-SCI climbs after ESMO data for lead asset Multikine2023-10-23 15:35:21 ET
For further details see:
CEL-SCI climbs after ESMO data for lead asset MultikineMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Cel-Sci Corporation Company Name:
CVM Stock Symbol:
Market:
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...
CEL-SCI Corp (NASDAQ:CVM) shares are trading higher by 18.6% to $1.98 during Wednesday’s session after the company received positive feedback...